Natera announced that its personalized and tumor-informed molecular residual disease, MRD, test, Signatera, has met coverage requirements from the Centers for Medicare & Medicaid Services’ CMS Molecular Diagnostics Services Program MolDX in two new indications: ovarian cancer in the adjuvant and surveillance settings, and breast cancer in the neoadjuvant setting. These determinations add to a growing list of covered indications for Signatera, including adjuvant and recurrence monitoring coverage in colorectal cancer, muscle-invasive bladder cancer, and breast cancer; and pan-cancer immunotherapy response monitoring. Ovarian Cancer The MolDX coverage decision applies to patients with ovarian cancer, in both the adjuvant and surveillance settings. Ovarian cancer is the 5th leading cause of cancer-related death among women, with an estimated 2022 incidence and mortality of 19,880 and 12,810, respectively, and a median age at diagnosis of 63 years. While multiple new treatment options have been introduced in recent years, physicians have had to rely on imperfect biomarkers to determine who is likely to benefit from these more intensive regimens, and recurrence risk remains high2. Additionally, current guidelines for surveillance are limited and providers often rely on tools with low sensitivity and specificity, such that a significant unmet need remains for these patients.3 Signatera performance in ovarian cancer was validated in a blinded, multi-site study published in Gynecologic Oncology.4 The study analyzed 163 plasma samples from 69 patients with stage I-IV ovarian cancer. Test performance was evaluated at multiple time points: pre-surgery, post-surgery prior to adjuvant treatment, and longitudinally. With longitudinal testing, recurrence was detected with 100% sensitivity
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTRA:
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James
- Jury rules in favor of Natera in patent infringement lawsuit against CareDx
- CareDx found to have not infringed on one Natera patent, infringed on another
- Wolfe reiterates Outperform on Natera after favorable jury decision